Just one year ago, Bristol-Myers Squibb's days as an independent entity seemed numbered. But thanks to the resolution of the Plavix crisis, innovative deal-making, and an R&D pipeline surging with specialty-focused products, the company is now thriving. In a free-wheeling Q&A, Bristol's R&D gurus, Francis Cuss and Elliott Sigal, discuss the need for a new kind of biopharma that is specialty-focused and technology agnostic.

Just one year ago, Bristol-Myers Squibb's days as an independent entity seemed numbered. But thanks to the resolution of the Plavix crisis, innovative deal-making, and an R&D pipeline surging with specialty-focused products, the company is now thriving. In a free-wheeling Q&A, Bristol's R&D gurus, Francis Cuss and Elliott Sigal, discuss the need for a new kind of biopharma that is specialty-focused and technology agnostic.

Even though Roche has been the single most successful investment in Big Pharma--because Roche has been the single most successful investor in Big Pharma--productivity over the past few years was slowed by leadership bottlenecks, misalignment among functions, and roadblocks to creativity. Roche's brand-new research boss, Lee Babiss, says a new decentralized structure and a more aggressive out-partnering strategy is designed to address the issues, manage risk, and spur post-2015 growth